Agios Pharm (AGIO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Agios Pharm (AGIO) has a cash flow conversion efficiency ratio of -0.056x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-57.31 Million) by net assets ($1.03 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is Agios Pharm worth for the company's overall valuation and market capitalisation.
Agios Pharm - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how Agios Pharm's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Agios Pharm Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Agios Pharm ranked by their cash flow conversion efficiency. Explore Agios Pharm earnings quality ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hefei Metalforming Mach Tool
SHG:603011
|
-0.003x |
|
Dentsply Sirona Inc
NASDAQ:XRAY
|
0.073x |
|
Investis Holding SA
SW:IREN
|
0.016x |
|
THE BK N.T.BUTTERF.+S.NEW
F:4IK
|
0.056x |
|
Jinko Power Technology Co Ltd
SHG:601778
|
0.081x |
|
Aecon Group Inc.
TO:ARE
|
0.062x |
|
Brightstar Lottery PLC
NYSE:BRSL
|
0.078x |
|
INOX India Limited
NSE:INOXINDIA
|
0.063x |
Annual Cash Flow Conversion Efficiency for Agios Pharm (2011–2025)
The table below shows the annual cash flow conversion efficiency of Agios Pharm from 2011 to 2025. View today's stock price for Agios Pharm for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $1.19 Billion | $-372.98 Million | -0.313x | -23.57% |
| 2024-12-31 | $1.54 Billion | $-389.84 Million | -0.253x | +30.70% |
| 2023-12-31 | $811.02 Million | $-296.06 Million | -0.365x | -29.85% |
| 2022-12-31 | $1.10 Billion | $-309.48 Million | -0.281x | +10.83% |
| 2021-12-31 | $1.29 Billion | $-407.32 Million | -0.315x | +56.68% |
| 2020-12-31 | $399.50 Million | $-290.76 Million | -0.728x | -25.78% |
| 2019-12-31 | $640.53 Million | $-370.62 Million | -0.579x | -30.68% |
| 2018-12-31 | $687.54 Million | $-304.42 Million | -0.443x | +41.71% |
| 2017-12-31 | $375.50 Million | $-285.23 Million | -0.760x | -806.36% |
| 2016-12-31 | $358.59 Million | $38.56 Million | 0.108x | +148.23% |
| 2015-12-31 | $345.12 Million | $-76.95 Million | -0.223x | -59.42% |
| 2014-12-31 | $424.37 Million | $-59.35 Million | -0.140x | +67.39% |
| 2013-12-31 | $131.48 Million | $-56.40 Million | -0.429x | +62.00% |
| 2012-12-31 | $43.90 Million | $-49.55 Million | -1.129x | -368.27% |
| 2011-12-31 | $63.14 Million | $-15.22 Million | -0.241x | -- |
About Agios Pharm
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment… Read more